<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628043</url>
  </required_header>
  <id_info>
    <org_study_id>EPO316 JP</org_study_id>
    <nct_id>NCT00628043</nct_id>
  </id_info>
  <brief_title>Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients</brief_title>
  <official_title>A Phase Ⅲ Randomized Double-Blind Placebo-Controlled Study of Epoetin Beta for the Treatment of Chemotherapy-Induced Anemia (CIA) in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <brief_summary>
    <textblock>
      This is a study to investigate the clinical efficacy and safety of epoetin beta 36,000 IU
      compared with placebo when administrated subcutaneously (s.c.) once-weekly for 12 weeks to
      anemic patients with lung cancer or gynecologic cancer undergoing chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of the subjects who receive red blood cell (RBC) transfusion and/or hemoglobin (Hb) concentration &lt; 8.0 g/dL</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hb</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FACT- total Fatigue Subscale score (FSS)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for RBC transfusion</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>EPOCH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin beta</intervention_name>
    <description>Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks</description>
    <arm_group_label>EPOCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subcutaneous administration of placebo once-weekly for 12 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lung cancer or gynecologic cancer patients

          -  Undergoing platinum-based chemotherapy repeated for ≧ 2 cycles after erythropoietin
             (EPO) or placebo administration

          -  8.0 g/dL ≦ hemoglobin concentration (Hb) ≦ 10.0 g/dL

          -  20 - 79 years old

          -  Performance status: 0 - 2

          -  No iron deficiency anemia

        Exclusion Criteria:

          -  Red blood cell transfusion within 4 weeks before treatment

          -  Erythropoietin therapy within 8 weeks before treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshito Suzuki</last_name>
    <role>Study Chair</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chubu Region</name>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chugoku/Shikoku Region</name>
      <address>
        <city>Chugoku/Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido/Tohoku Region</name>
      <address>
        <city>Hokkaido/Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto/Koshinetsu Region</name>
      <address>
        <city>Kanto/Koshinetsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki/Hokuriku Region</name>
      <address>
        <city>Kinki/Hokuriku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu Region</name>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2008</study_first_submitted>
  <study_first_submitted_qc>March 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2008</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chugai Pharmaceutical Co., Ltd.</name_title>
    <organization>Chugai Pharmaceutical Co., Ltd.</organization>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>patients</keyword>
  <keyword>with</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>induced</keyword>
  <keyword>anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

